THE EBB AND FLOW OF TYPE 2 DIABETES: FROM PREVENTION TO DEPRESCRIBING (DC-018)

Saturday, October 28, 2023

11:00 – 12:00 EST

Location: Palais, 517BC

Presenter(s)

Harpreet S. Bajaj, MD, MPH, ECNU, FACE (he/him/his)

Endocrinologist & Medical Director, Endocrine and Metabolic Research
LMC Healthcare
Diabetes Canada
Susie Jin, RPh CDE CRE (she/her/hers)

Pharmacist, Certified Diabetes Educator, Certified Respiratory Educator
self-employed

Handouts
Sonja M. Reichert, MD, MSc, CCFP, ABOM Diplomate (she/her/hers)

Family Physician, Associate Professor, Clinician Researcher
St. Joseph's Primary Care Diabetes Support Program, Western University
Western University
JL

Julia Lemire
Loredana Talos (she/her/hers)

Nurse Practitioner Adult Care - Endocrinology
Mcgill University Health Center
Mcgill University Health Center

Disclosure(s):

Harpreet S. Bajaj, MD, MPH, ECNU, FACE: Amgen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Anji: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); AstraZeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Boehringer Ingelheim: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Eli Lilly: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Kowa: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Susie Jin, RPh CDE CRE: Abbott: Consultant/Advisory Board (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eisai: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); eli lilly: Speaker/Honoraria (Ongoing); GlaxoSmithKline: Speaker/Honoraria (Ongoing); moderna: Speaker/Honoraria (Ongoing); NovoNordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing)

Loredana Talos: No financial relationships to disclose

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

Identify how to apply the different levels of prevention (Primordial, primary, secondary, tertiary and quaternary) in type 2 diabetes
Describe the utility of digital technologies to aid prevention of type 2 diabetes, including results of the Canadian Diabetes Prevention Program
Apply strategies to safely support type 2 diabetes remission through medication deprescription
Assess and initiate practical deprescribing strategies in older adults with diabetes
Recognize the perspective and lived experiences of individuals affected by type 2 diabetes with respect to Deprescribing and Remission of Diabetes